Updated
Residents
who rotate on the infectious diseases service have clinical rotations on the
inpatient General Infectious Diseases Consultation Service, the inpatient
Immunocompromised Host Infectious Diseases Consultation Service, or both. Most
residents will split the rotation equally between the two inpatient services. A
packet of articles is available for reading. Residents are also given a series
of questions to be answered by the end of the rotation (post-test).
1. Li JS, et al. Proposed
modifications to the Duke criteria for the diagnosis of infective endocarditis.
Clinical Infectious Diseases 1999; 30: 633-638.
2. Durack D, et al. New
criteria for diagnosis of infective endocarditis: utilization of specific
echocardiographic findings. American
Journal of Medicine 1994; 96: 200-209.
3. Bartlett
J, et al. Practice guidelines for the management of community-acquired
pneumonia in adults. Clinical Infectious Diseases 2000; 31: 347-382.
4. Garau J. Treatment of
drug-resistant pneumococcal pneumonia. Lancet Infectious Diseases 2002; 2:
404-415.
5. O’Grady NP, et al. Guidelines for the prevention of intravascular
catheter-related infections. Clinical Infectious Diseases 2002; 35:
1281-1307.
6. Mermel LA, et al. Guidelines for the management of
intravascular catheter-related infections. Clinical Infectious Diseases
2000; 32: 1249-1272.
7. Hooper D. Fluoroquinolone
resistance among Gram-positive cocci. Lancet Infectious Diseases 2002; 2:
530-538.
8. Hiramatsu K.
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic
resistance. Lancet Infectious Diseases 2001; 1: 147-155.
9. Bonten MJM, et al. Vancomycin-resistant
enterococci: why are they here, and where do they come from? Lancet Infectious
Diseases 2001; 1: 314-325.
10. Van Der Poll T.
Immunotherapy of sepsis. Lancet Infectious Diseases 2001; 1:165-174.
11.
12. O’Grady NP, et al. Practice
guidelines for evaluating new fever in critically ill adult patients. Clinical
Infectious Diseases 1998; 26: 1042-1059.
13. Stengel D, et al. Systematic
review and meta-analysis of antibiotic therapy for bone and joint infections.
Lancet Infectious Diseases 2001; 1: 175-188.
14. Liewelyn M, et al.
Superantigens: microbial agents that corrupt immunity. Lancet Infectious
Diseases 2002; 2: 156-162.
15. Wirsing CH. Pertussis of
adults and infants. Lancet Infectious Diseases 2002; 2: 744-750.
16. American Thoracic Society,
CDC, and IDSA. Treatment of tuberculosis. MMWR Recommendations and Report,
2003; 52 (RR11): 1-77.
17. Hengge UR, et al. Lyme
borreliosis. Lancet Infectious Diseases 2003; 3: 489-500.
18. Wormser GP, et al. Practice
guidelines for the treatment of Lyme disease. Clinical Infectious Diseases
2000; 31: S1-S14.
19. Pappas P, et al. Guidelines
for the treatment of candidiasis. Clinical Infectious Diseases 2004; 38:
161-189.
20. Canuto MM, et al. Antifungal
drug resistance to azoles and polyenes. Lancet Infectious Diseases 2002; 2:
550-563.
21. Saag MS, et al. Practice
guidelines for the management of cryptococcal disease. Clinical Infectious
Diseases 2000; 30: 710-718.
22. 2001 USPHS / IDSA Guidelines
for the prevention of opportunistic infections in persons infected with human
immunodeficiency virus.
23. Department of Health and
Human Services. Guidelines for the use of antiretroviral agents in HIV-1
infected adults and adolescents.
24. Nunez M, et al. Treatment of
chronic hepatitis B in the human immunodeficiency virus-infected patient:
present and future. Clinical Infectious Diseases 2003; 37:1678-1685.
25. CDC et al. Recommendations
for incorporating HIV prevention into the medical care of persons living with
HIV. Clinical Infectious Diseases 2004; 38: 104-121.
26. Rupprecht CE, et al. Rabies
re-examined. Lancet Infectious Diseases 2002; 2: 327-343.
27.
28. Ramasamy I, et al. Organ
distribution of prion proteins in variant Creutzfeldt-Jakob disease. Lancet
Infectious Diseases 2003; 3: 214-222.
29. Monnath TP. Yellow fever: un update. Lancet Infectious Diseases 2001; 1: 11-20.
30. Yuan MF, et al. Treatment of
chronic hepatitis B. Lancet Infectious Diseases 2001; 1: 232-241.
31. Guzman MG, et al. Dengue: an
update. Lancet Infectious Diseases 2001; 2: 33-42.
32. Salgado CD, et al. Influenza
in the acute hospital setting. Lancet Infectious Diseases 2002; 2: 145-155.
33. Winstanley P. Modern
chemotherapeutic options for malaria. Lancet Infectious Diseases 2001; 1:
242-250.
34. Carpio A.
Neurocysticercosis: an update. Lancet Infectious Diseases 2002; 2: 751-762.
General
Infectious Diseases Clinical Curriculum:
1.
Evaluation and management of the patient with fever
a. Community-acquired febrile
illness
b. Nosocomial febrile illness
c. Fever of unknown origin
(FUO)
d. Management of fever in AIDS
and HIV
e. Post-partum fever
2.
Community-acquired infections
a. Upper and lower respiratory
infections
b. Urinary tract infections
c. Skin and soft tissue
infections
d. Septic arthritis and
osteomyelitis
e. Endocarditis, catheter
sepsis, and other intravascular infections
f.
CNS infections-meningitis, encephalitis, and brain abscess
g. Intraabdominal infections
h. Gastrointestinal infections,
and food poisoning
i.
Infections related to trauma, burns, and bite wounds
j.
Infections of reproductive organs
k. Ocular infections
l.
3.
Nosocomial infections
a. Pneumonia
b. Urinary tract infections
c. Wound infections
d. Septicemia, candidemia, and
intravenous catheter sepsis
e. Other nosocomial infections
4.
Sepsis syndrome and septic shock
a. Pathophysiology
b. Clinical manifestations,
including ARDS and DIC
c. Management, including the
use of antibiotics, biological agents and steroids
d. Toxic shock syndromes
5.
Sexually transmitted diseases
a. Urethritis
b. Genital ulcers
c. Cervicitis
d. Pelvic inflammatory disease
e. Syphilis
f.
Other sexually transmitted diseases
6.
Tuberculosis and atypical mycobacterial infections
a. Pulmonary TB
b. Extrapulmonary TB
c. PPD reactor
d. TB in HIV and other immune
deficiency states
e. Atypical mycobacterial
infections
f.
Antimycobacterial agents
7.
Fungal infections
a. Endemic fungal infections
b. Opportunistic fungal
infections
c. Antifungal agents
8.
HIV Infection
a. Epidemiology of HIV
infection
b. Prophylaxis of transmission
i.
Post-exposure prophylaxis
ii.
Vertical transmission prophylaxis
c. Diagnosis of chronic and
acute HIV infection
d. Immunology of HIV infection
e. General clinical
manifestations
i.
Acute HIV infection
ii.
Chronic, uncomplicated HIV infection
iii.
Non AIDS-defining complications of HIV, including:
1. Autoimmune complications
2. Metabolic complications
3. Neurological diseases
iv.
AIDS-Defining conditions, including:
1. Opportunistic infections
2. Malignancy
3. Wasting syndrome and other
AIDS-defining conditions
f.
Prophylaxis and management of opportunistic infections
g. Management of other
AIDS-related conditions
h. Antiretroviral therapy
i.
Indications
ii.
Initiation of therapy
iii.
Testing for efficacy of therapy and for resistance to therapy
iv.
Salvage regimen
v.
Complications of therapy
9.
Viral hepatitis
a. Hepatitis A, B, C, D, E, a
b. EBV, CMV, HSV, adenovirus
c. Therapy of chronic viral
hepatitis
10.
Infections in IV drug users
11.
Infections in travelers
12.
Infections in geriatric patients
13.
Infections during Pregnancy
14.
Antimicrobial Agents
a. Classes of drugs
(antibacterial, antiviral, antifungal, and antiparasitic agents)
b. Pharmacokinetics
c. Mechanisms of antimicrobial
resistance
d. Interpretation of
susceptibility results
e. Adverse effects, drug
interactions and contra-indications
f.
Allergy and pseudo-allergy
g. Use in pregnancy
h. Dose adjustment in liver and
renal failure
i.
Monitoring therapy including drug levels
15.
Immunization of adults
16.
Hospital Epidemiology and Infection Control
a. Surveillance for nosocomial
infections
b. Outbreak evaluation
c. Strain typing
d. Isolation and other
infection control measures
e. Employee Health Evaluation
f.
Precautions for blood-borne pathogens, including evaluation and
post-exposure prophylaxis for HBV, HCV, syphilis, and HIV infection
35. Rosen FS, et al. The
Primary immunodeficiencies.
36. Hughes WT, et al. 2002
Guidelines for the use of antimicrobial agents in neutropenic patients with
cancer. Clinical Infectious Diseases 2002; 34:730-751.
37. Buckley, RH. Transplantation
immunology: organ and bone marrow. Journal of Allergy Clinical Immunology
2003; 111:S733-S744
38. Pursell, K. Handout on
immunosuppression.
39. Avery RK. Recipient
screening prior to solid-organ transplantation. Clinical Infectious
Diseases 2002; 35:1513-1519.
40. Delmonico, FL. Cadaver
donor screening for infectious agents in solid organ transplantation.
Clinical infectious diseases 2000; 31:781-786.
41. Fishman, FA, et al. Infections
in organ-transplant recipients.
42. Sable, CA, et al. Infections
in bone marrow transplant recipients. Clinical Infectious Diseases 1994;
18:273-281.
43.
44. Herbert, H, et al. Management
of Cytomegalovirus Infection after solid-organ or stem-cell transplantation.
Drugs 1998; 55: 59-72.
45. Zaia, JA. Prevention and
management of CMV-related problems after hematopoietic stem cell
transplantation. Bone Marrow Transplantation 2002; 29:633-638.
46. Kwak, EJ, et al.
Pathogenesis and management of polyomavirus infection in transplant recipients.
Clinical Infectious Diseases 2002; 35: 1081-1087.
47.
48.
49. Soave, R. Prophylaxis
strategies for solid-organ transplantation. Clinical Infectious Diseases 2001;
33: S26-S31.
50. Duchini, A,
et al. Vaccinations for adult solid-organ transplant recipients: current
recommendations and protocols. Clinical Microbiology Reviews 2003; 16: 357-364.
Immuno-Compromised Host Clinical Curriculum:
Infections in transplant patients:
1. Risk Factors and Approach to
Transplant Infectious Diseases
a. Host factors
b. Effect of type of transplant
c. Immunosuppressive therapy
2. Infecting Microbial Agents
3. Diagnosis
a. Role of the microbiology lab
b. Other diagnostic testing
4. Monitoring for infection
5. Prophylaxis
6. Infection Control Measures
7. Approach to Fever in the
Transplant Patient
8. Infections in Stem Cell
Transplant Recipients
a. Basic techniques of stem
cell transplantation
b. Syndromes unique to stem
cell transplantation
c. Patterns of infection at
different time points post-transplant
d. Individual infections
e. Methods of immune reconstitution
9. Infections in solid organ
transplantation
a. Time of occurrence of
infections of infections after transplantation
b. Types of transplants
10. Sites and types of
infections
11. Specific problems with
herpes viruses
12. Lymphoproliferative disease
and EBV